The influence of lung deposition on clinical response

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 14, Issue SUPPL. 1, 2001, Pages

  Pritchard, J N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Asthma; Chronic obstructive disease; Efficacy; Lung deposition; Metered dose inhalers

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; SALBUTAMOL;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; PARTICLE SIZE; REVIEW;

EID: 0035117761     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680150506303     Document Type: Review

References (20)

1. Lung deposition of budesonide inhaled via Turbuhaler®: A comparison with terbutaline sulphate in normal subjects
2. Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes
3. Investigation and assessment of airway and lung inflammation: We now have the tools, what are the questions?
4. Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance
5. A comparison of salbutamol given via Diskus or Turbohaler
6. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices
7. On the relative therapeutic index between formoterol Turbuhaler® and salbutamol pressurized metered dose (pMDI) inhaler in asthmatic patients
8. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids
9. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
10. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler® and the Diskus® powder devices in healthy subjects
11. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI
12. A mathematical model of mass deposition in man
13. Correlation of cascade impactor data with measurements of lung deposition for pharmaceutical aerosols
14. Interpretation of in vitro particle size data from dry powder inhalers
15. Deposition patterns of polydisperse aerosols within human lungs
16. Beneficial effects with reduced particle size and CFC-free extrafine aerosol steroid on lung deposition, absorption, efficacy and safety
17. Improvement in topical lung vs systemic availability of beclomethasone dipropionate from an extrafine aerosol formulation
18. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics
19. Pharmacokinetic profile of improved lung delivery, with CFC-free ultrafine aerosol steroid inhaler
20. 1 as HFA-BDP